Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.

Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil

Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2019 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Why Is Spectrum Pharma (SPPI) Down 1.1% Since Last Earnings Report?

Spectrum Pharmaceuticals had to withdraw its Biologics License Application (BLA) of ROLONTIS after the FDA requested additional information.

Spectrum Suffers BLA Setback, But Based On Deadline, It Was For The Better

Spectrum Pharmaceuticals Inc. shares slid 7.6% in premarket trade Friday.

Spectrum Pharma withdraws license application for Rolontis after FDA seeks information on manufacturing

News for Spectrum Pharma Stock (SPPI)